Novartis: lower relapse rate in multiple sclerosis.
(CercleFinance.com) - Children and adolescents with multiple sclerosis had an 82% lower relapse rate with Gilenya compared to interferon beta-1a, Novartis said at a medical congress last weekend.
The new data also show patients treated with Gilenya had significantly fewer new brain lesions versus those on interferon beta-1a, the Swiss biopharmaceutical company said.
Results of the phase III study, investigating the safety and efficacy of oral Gilenya in children aged 10 to 17 over a period of up to two years, have been presented yesterday at the ECTRIMS-ACTRIMS congress in Paris.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The new data also show patients treated with Gilenya had significantly fewer new brain lesions versus those on interferon beta-1a, the Swiss biopharmaceutical company said.
Results of the phase III study, investigating the safety and efficacy of oral Gilenya in children aged 10 to 17 over a period of up to two years, have been presented yesterday at the ECTRIMS-ACTRIMS congress in Paris.
Copyright (c) 2017 CercleFinance.com. All rights reserved.